GCA Advises Micro-Macinazione on Its Sale to Lonza
Micro-Macinazione is a contract manufacturer that provides micronization services for the pharmaceutical and fine chemical industries. Micronization is often seen as key to improving the bioavailability of active pharmaceutical ingredients. With improved bioavailability, lower drug doses can be prescribed, potentially reducing a patient’s side effects.
Its acquisition of Micro-Macinazione expands Lonza’s existing clinical and commercial manufacturing capabilities in micronization. Lonza sees micronization as an attractive technology, given its applications across many of the high growth areas of the pharmaceutical market.
Markus Arigoni, CEO of Micro-Macinazione, commented: “By combining with Lonza, we are creating a global leader with the ability to provide customers both in the US and Europe access to the micronization technologies and manufacturing capabilities they need to bring novel drugs to the market faster and more efficiently.”
GCA is a premier global investment bank serving a broad client base through a range of advisory services including mergers and acquisitions, debt and equity capital markets, private funds, restructuring, and asset management. GCA is a global advisor providing insightful advice and is focused on building long-term relationships based on trust. GCA delivers deep expertise in many key industries and has a particular focus in Technology, Software, Media, Digital Media, Communications, Industrials and Industrial Technology, Healthcare, Financial Institutions, FinTech and Business Services. GCA has teams of highly experienced bankers in San Francisco, New York, Tokyo, Frankfurt, London, Manchester, Milan, Mumbai, Munich, New Delhi, Osaka, Shanghai, Singapore, Tel Aviv and Zurich. For more information, visit gcaglobal.com.